Also known as Janumet 50/1000, Janumet 50/500, Janumet 100/1000, Juvisync 100/10, Juvisync 100/20, Juvisync 100/40, and Januvia
Sitagliptin (INN; previously identified as MK-0431 and marketed as the phosphate salt under the trade name Januvia) is an oral antihyperglycemic (antidiabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It was developed, and is marketed, by Merck & Co. This enzyme-inhibiting drug is used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for treatment of diabetes mellitus type 2. The benefit of this medicine is its fewer side effects (e.g., less hypoglycemia, less weight gain) in the control of blood glucose values. While safety is its advantage, efficacy is often challenged as it is often recommended to be combined with other agents like metformin.Source: Wikipedia
Estimated Total Cost: $176.91 for an average of 28 days supply
Patients are most commonly prescribed sitagliptin to treat diabetes, diabetic peripheral neuropathy, kidney disease due to longstanding hypertension, and diabetic kidney disease.